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Abstract: It is widely known that cells from epithelial tumors, e.g., breast cancer, detach 
from their primary tissue and enter blood circulation. We show that the presence of 
circulating tumor cells (CTCs) in samples of patients with primary and metastatic breast 
cancer can be detected with an array of selected tumor-marker-genes by reverse 
transcription real-time PCR. The focus of the presented work is on detecting differences in 
gene expression between healthy individuals and adjuvant and metastatic breast cancer 
patients, not an accurate quantification of these differences. Therefore, total RNA was 
isolated from blood samples of healthy donors and patients with primary or metastatic 
breast cancer after enrichment of mononuclear cells by density gradient centrifugation. 
After reverse transcription real-time PCR was carried out with a set of marker genes 
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(BCSP, CK8, Her2, MGL, CK18, CK19). B2M and GAPDH were used as reference genes. 
Blood samples from patients with metastatic disease revealed increased cytokine gene 
levels in comparison to normal blood samples. Detection of a single gene was not 
sufficient to detect CTCs by reverse transcription real-time PCR. Markers used here were 
selected based on a recent study detecting cancer cells on different protein levels. The 
combination of such a marker array leads to higher and more specific discovery rates, 
predominantly in metastatic patients. Identification of CTCs by PCR methods may lead to 
better diagnosis and prognosis and could help to choose an adequate therapy. 
Keywords: breast cancer; circulating tumor cells; reverse transcription real-time PCR; 
marker genes 
 
1. Introduction 
One major characteristic of malignant tissue is their differently regulated gene expression levels in 
comparison to normal tissue [1]. Such genes with altered expression have also been found in breast 
cancer with the help of microarray analysis screenings [2,3]. Among malignant diseases, breast cancer 
has the highest incidence worldwide and is the most frequent cause of death in women. However, the 
primary tumor is almost never lethal, whereas remote metastases and the total growing tumor mass 
lead to the patients’ death. Metastatic events occur when cells dissolve from the primary tumor, 
circulate via the blood stream or the lymphatic system to other organs, then evade into the new 
environment and become secondary tumors [4–6]. The incidence of these so-called “Circulating 
Tumor Cells” (CTCs) is linked to a worse prognosis for the patients´ survival time [7,8]. Thus, the 
detection of CTCs from peripheral blood samples could be a useful tool in diagnosis, prognosis and 
planning of further therapeutic steps. Since CTCs have largely the same genetic characteristics as the 
primary tumor and are therefore distinguishable from normal blood cells, a reverse transcription  
real-time PCR-based approach for the discovery of CTCs could constitute an easy, reliable and highly 
efficient method. 
Here we present a TaqMan® PCR assay using six marker genes which are known to be upregulated 
in breast cancer cells. We used Cytokeratin-8, -18 and -19 genes (CK8, CK18, CK19) known to be 
expressed on epithelial cells, such as CTCs, but not on blood cells. Moreover, immunocytochemical 
stainings (e.g., APAAP) use CK8, CK18, and CK19 routinely in cancer diagnosis [9,10]. As an 
additional marker, we used Mammaglobin (MGL) which is only expressed in the adult mammary 
gland and is known to be upregulated in breast cancer [11]. Synuclein gamma, also called Breast 
Cancer Specific Protein (BCSP), is highly expressed in advanced infiltrating breast cancer and is 
known as a marker for recurrence of the disease and formation of metastases [12–15]. BCSP-positive 
cells show a higher resistance to standard chemotherapy like paclitaxel than BCSP-negative/BCSP-low 
expressing cells [16,17]. The last marker used in this study is c-erbB2 (Her2), which is over-expressed 
in 20% of breast cancers and is also responsible for the aggressiveness of the tumor [18–20]. The big 
difference of Her2 expression in normal and cancer cells makes it a key target for several therapeutic 
approaches [21–23]. Furthermore Her2 was already shown to be a useful marker for Q-PCR, rendering 
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equal or better values for detection sensitivity, specificity and positive and negative predictive  
values [24,25]. 
The above-mentioned markers were comparatively analyzed in blood samples withdrawn from 
adjuvant and metastatic breast cancer patients during surgery The gene expression levels of as well 
adjuvant as metastatic breast cancer patients were normalized to levels in blood samples of 20 healthy 
donors, considered as negative control group. Our intention was to detect differences in gene 
expression between the three sample groups and to find a signature of marker genes for CTCs in breast 
cancer by Real-Time-PCR. 
2. Results and Discussion 
2.1. Results  
2.1.1. Expression of CK8, 18, and 19 in Patients with Primary Carcinoma Undergoing Adjuvant Therapy  
In the adj. group (respective tumor biomarker data are shown in Table 1), two samples show a 
simultaneous upregulation of CK8 and CK19 (Figure 1a, adj. 6 and adj. 8). In six further samples only 
CK8 and in two more samples only CK19 show relative expression values >1. In four cases all three 
examined genes are downregulated (Figure 1a, adj. 2, adj. 5, adj. 9 and adj. 10). Remarkably, all 
samples display expression values <1 or downregulation of CK18 in all patients. Furthermore, it is 
noteworthy that patient sample adj. 6 shows a more that 10-fold upregulated expression level of CK19. 
Figure 1. (a,b) Expression of the used marker genes in the adjuvant situation. 
 
(a) (b) 
Table 1. Tumor Biomarker Data of adjuvant patients. 
Patient Histology T-stage N-stage Her2-status Estrogen receptor (%) Progesterone receptor (%) 
Adj.1 Inv. ductal pT2 pN3 +++ 0 0 
Adj.2 Inv. ductal pT1c pN0 ++ 90 90 
Adj.3 Inv. ductal pT2 pN0 - 90 90 
Adj.4 Inv. lobular pT1c pN0 - 95 90 
Adj.5 Inv. ductal pT2 pN0 - 30 50 
Adj.6 Adeno-squamous pT3 pN0 +++ 0 0 
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Table 1. Cont. 
Patient Histology T-stage N-stage Her2-status Estrogen receptor (%) Progesterone receptor (%) 
Adj.7 Inv. ductal pT1c pN3a + 80 50 
Adj.8 Inv. ductal pT2 pN3a +++ 30 10 
Adj.9 Inv. ductal pT2 pN0 + 0 10 
Adj.10 Inv. ductal pT1c pN0 ++ 90 60 
Adj.11 
Adenocarcinoma 
Lobular 
pT2 pN1 + 80 30 
Adj.12 Inv. ductal pT2 pN0 - 90 30 
Adj.13 Inv. ductal pT2 pN0 + 80 80 
Adj.14 Inv. ductal pT1c pN0 - 0 0 
2.1.2. Expression of BCSP, Her2, and MGL in Patients with Primary Carcinoma Undergoing  
Adjuvant Therapy 
In the same group of patients, we find only one case with two simultaneously upregulated genes 
(Figure 2, BCSP and Her2, adj. 1). In contrast to this, there are five cases with all three genes 
downregulated (Figure 1b, adj. 5, adj. 7, adj. 10, adj. 11, adj. 12). For one patient sample (adj. 9), no 
relative expression value could be calculated due to weak fluorescence signals that did not reach 
detection thresholds during the reverse transcription real-time PCR reaction. In only four cases MGL 
or Her2 show relative expression levels greater than 1 and in only one case (adj. 1) BCSP is 
upregulated in comparison to the reference level. 
Figure 2. (a,b) Expression of the used marker genes in the metastatic setting. 
 
(a) (b) 
2.1.3. Expression of CK8, 18, and 19 in Metastatic Patients 
Regarding cytokeratin 8, 18, and 19 in metastatic patients (respective tumor biomarker data are shown 
in Table 2) CK8 is found upregulated in 6 out of 11 cases (Figure 2a, met. 2, met. 3, met. 4, met. 7, met.8, 
and met. 11); CK18 and CK19 show relative expression levels >1 in only one and two cases, respectively. 
In one sample (met. 4) CK8 and CK18 exhibit relative expression values suggesting an upregulation in 
comparison to the reference sample. For CK19 there is an intriguing finding: 9 out of 11 expression 
values were barely detectable and didn’t reach the threshold. In stark contrast to these findings, the 
other two expression values for CK19 (Figure 2a, met. 9 and met. 10) revealed a strong upregulation. 
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Table 2. Tumor Biomarker Data of metastatic patients. 
Patient Histology T-stage N-stage Metastases 
Her2-
status 
Estrogen 
receptor (%) 
Progesterone 
receptor (%) 
Met.1 Inv. ductal pT2 pN0 Liver, Bones - 0 0 
Met.2 Inv. ductal pT2 pN0 Brain +++ 0 0 
Met.3 Inv. ductal pT4 pN0 Bones + 0 0 
Met.4 Inv. ductal pT4 pN1 Lung ++ 0 0 
Met.5 Inv. ductal pT4 pN0 Lung + 60 40 
Met.6 Inv. ductal pT1c pN0 Bones, Liver - 0 0 
Met.7 Inv. ductal pT2 pN0 Liver + 0 0 
Met.8 Inv. ductal pT3c pN1 Liver, Bones, Brain - 0 0 
Met.9 Inv. ductal pT3 pN0 Bones +++ 20 10 
Met.10 Inv. ductal pT2 pN1 Lung, Bones - 30 10 
Met.11 Inv. ductal pT1b pN0 Bones - 90 70 
2.1.4. Expression of BCSP, Her2, and MGL in Metastatic Patients 
MGL, BCSP, and Her2 show a simultaneous downregulation in 5 out of 11 cases evaluated in this 
study. A concurrent upregulation of two genes can only be noticed in one case (Figure 2b,  
met. 4: BCSP and Her2). MGL alone shows an expression value >1 in only one case (met. 8), whereas 
8 of the other 10 cases seem to have such low expression values, that further calculations were not 
possible, e.g., CK19 (Figure 2). BCSP and Her2 show higher expression levels than the reference 
sample in four and two cases, respectively (met. 2, met. 4, met. 7 and met. 10; met. 4 and met. 11). 
2.2. Discussion 
Real-Time PCR based techniques were already used for solid tumor profiling and are considered to 
be objective, robust and cost-effective molecular techniques, that could be used in daily cancer 
diagnostic routine [26]. We are now presenting a reverse transcription real-time PCR assay for the 
detection of Circulating Tumor Cells from peripheral blood, rendering the advantage for the patient, 
that no biopsies or bone marrow aspirations have to be withdrawn for the analysis. 
Results of our study showed that cytokeratin genes seem to be the most promising markers for the 
detection of CTCs from peripheral blood of breast cancer patients with reverse transcription real-time 
PCR (TaqMan). The most suitable marker of the cytokeratin array used in our study is CK8 mRNA, 
rendering most expression values >1, whereas CK18 mRNA, in contrast, only revealed one 
significantly upregulated value in the metastatic group. 
MGL, BCSP, and Her2 mRNA show few expression values >1 as well in adjuvant as in metastatic 
patients. However, in both settings we observed five samples where all three genes were 
simultaneously downregulated in comparison to the reference sample. Altogether, higher amplitudes 
for these three genes were detected in the adjuvant setting (Figure 1b vs. Figure 2b). CTCs can be 
detected from peripheral blood by Real-Time-PCR, using the cytokeratin markers, especially 
cytokeratin 8. But one single marker gene alone is not sufficient for PCR-based detection of circulating 
tumor cells from peripheral blood samples. Using a combination of different marker genes highly 
increases the chance for detection of CTCs, especially in samples of metastatic patients.  
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Some of the samples show different expressions for Her-2 in primary tumor vs. CTCs detected by 
Real-Time PCR (adj. 7–11, 13 and 14; met. 2–5, 7, 9 and 11; Figures 1b and 2b, Table 3). According 
to previous reports [27,28], a switch in Her-2 marker expression can occur. This phenomenon 
describes that CTCs can become positive for Her-2, even though the primary tumor is negative for 
Her-2 and vice versa. In the on hand study this switch can be seen in 50% of all samples in the 
adjuvant group and in 64% of the metastatic samples. 
Table 3. Number and percentages of c-erbB2 (Her2)-switches between primary tumor and 
circulating tumor cells (CTCs). 
Her2 Status 
Tumor/CTCs 
Adjuvant Metastatic 
Number % Number % 
+/+ 3/14 22% 1/11 9% 
+/− 1/14 7% 6/11 55% 
−/+ 6/14 43% 1/11 9% 
−/− 4/14 28% 3/11 27% 
Another caveat of the present study is the small number of samples, which leads to a weaker 
statistical significance in the obtained results. A minimum number of 50 to 100 patients per group 
should be included in order to deduct statistically confirmed results. On the other hand, it is rather 
difficult to collect such a large number of blood samples, especially from metastatic patients.  
To improve the detection of CTCs by Real-Time-PCR, more marker genes need to be tested; 
promising candidates are for example MMP13 [29–32], UBE2Q2 [33], Nectin-4 [34], and ALDH [35]. 
To avoid arduous collections of blood samples, both for physicians and patients, these markers should 
first be tested on blood samples mixed with different breast cancer cell line cells in a pilot in vitro 
study. Using these blood samples with a certain known number of cells derived from established breast 
cancer cell lines, standard curves could be collected and precious patient material could be saved at the 
same time. By the generation of standard curves a more accurate quantification of the gene expression 
values will also be possible. Here, we only focused on detection differences in gene expression levels 
between the sample groups, and found within this study two marker combinations for the adjuvant 
setting on and for metastatic patients. This method, already shown to be promising for multiparametric 
RNA analysis [36], could be of great clinical use for breast cancer diagnostics as well as prognosis and 
detection of micrometastasis using a multigene marker panel [37] and could serve as a further valuable 
tool to select appropriate and personalized therapeutic means. 
Some more methods for CTC detection are described in the literature for example by 
immunomagentic cell separation [38], by EPISPOT assays [39], by Flow Cytometry followed by  
Real-Time PCR [40] and by immunomagnetic cell enrichment also followed by Real-Time PCR [41]. 
These methods, although they might have a higher sensitivity and specificity, are much more 
laborious, expensive, and time consuming. The advantage of the Real-Time PCR based method for 
CTC detection from peripheral blood presented in the on hand study, is furthermore, that by using 
different marker combinations, which should be tested as a next experimental step, not only detection 
but simultaneous characterization of the CTCs could be possible. 
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3. Experimental Section  
3.1. Blood Samples 
A total of 20 mL blood was withdrawn in EDTA-tubes from healthy donors (n = 20), patients with 
primary breast carcinoma undergoing adjuvant therapy (adj., n = 14), and metastatic patients (n = 11) 
Tumor Biomarker data are shown in Tables 1–3. Blood samples were diluted to a volume of 50 mL 
with PBS (Biochrom, Berlin, Germany) and layered onto 2 × 25 mL Histopaque 1077 (Sigma-Aldrich, 
Taufkirchen, Germany), then centrifuged at 400× g for 30 min. Buffy Coat containing mononuclear 
cells was aspired and placed into a fresh tube. The suspension was filled up to 50 mL with PBS and 
spun down at 250× g for 10 min. This washing step was repeated once, then the supernatant was 
removed, the pellet was air-dried and frozen at −80 °C until use. 
3.2. Ethics Approval 
The study has been approved by the local ethics committee of the Ludwig-Maximilians University 
Munich (approval with the reference number 148-12) and has been carried out in compliance with the 
guidelines of the Helsinki Declaration of 1975. The study participants gave their written informed 
consent and samples and clinical information were anonymized for statistical workup. 
3.3. RNA Isolation 
Upon thawing, cell pellets were dissolved in 1 mL Trizol LS reagent (Invitrogen, Darmstadt, 
Germany) and 200 µL Chloroform (Merck, Darmstadt, Germany) was added. The suspension was 
mixed, stored on ice for 5 min and centrifuged at 12,000× g for 15 min at 4 °C. Upper clear phase was 
aspired and transferred into a fresh tube. A total of 500 µL cold isopropanol (Merck) and 2.5 µL 
glycogen (Invitrogen) were added. The solution was thoroughly mixed and frozen at −20 °C over 
night. RNA was precipitated by centrifugation at 12,000× g for 10 min at 4 °C. After removal of 
supernatant RNA-pellets were washed with 1 mL 75% Ethanol (Merck) by centrifugation at 12,000× g 
for 8 min at 4 °C. Then pellets were air-dried and dissolved in 20 µL DEPC-treated water. 
Concentration and ratio of isolated RNA were measured by Nanodrop-System-Nanophotometer 
(Implen, Munich, Germany), inhibition controls (by sample dilution) were carried out and RNA 
integrity was controlled by denaturing formaldehyde-gel electrophoresis. 
3.4. Reverse Transcription 
For reverse transcription an RNA-amount of 5 µg in a maximum volume of 8 µL in DEPC treated 
water was used. A total of 10 µL 2× RT reaction mix (containing oligo(dT)20 (2.5 µM), random 
hexameres (2.5 ng/µL), 10mM MgCl2 and dNTPs) and 2 µL RT enzyme mix (including SuperScript™ 
III RT and RNaseOUT™) (SuperScript III First Strand Synthesis Super Mix; Invitrogen) were added. 
The solution was incubated at 25 °C for 10 min and at 42 °C for 50 min. Following this step, 
polymerase was heat-inactivated at 85 °C for 5 min and subsequently chilled on ice. A total of 1 µL 
(2U) RNase H was added to the reaction and the whole solution was incubated at 37 °C for 20 min. 
The obtained cDNA was either subsequently processed or stored at −20 °C until use. 
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3.5. Nested PCR  
We performed a nested PCR for marker CK 8, 19 and BCSP. A total of 1µl of the prepared cDNA 
was mixed with 1 µL primer, 10.5 µL nuclease free water and 12.5 µL 2× PCR mastermix (Promega, 
Madison, WI, USA). The samples were processed on Eppendorf Master Cycler (Eppendorf, Hamburg, 
Germany). Settings for the PCR runs are: one enzyme activation cycle at 98 °C for 30 s, 34 cycles at 
98 °C for 15 s, 57 °C for 30 s, 72 °C for 2 min and one terminatory cycle at 72 °C for 5 min. The 
obtained PCR product was either processed or stored at −20 °C until use. The primer sequences are 
presented in Table 4. 
Table 4. Primer used for nested PCR.  
Gene  Forward primer Reverse primer 
CK8 5'-cgtcaagctgctggac-3' 5'-aggctgtagcggccgg-3' 
CK19 5'-gcctggttcaagccgg-3' 5'-ctcctgattcccgctc-3' 
BCSP 5'-acactgtgtggccaagac-3' 5'-ccactctgggtctgcc-3' 
3.6. Real-Time RT-PCR (TaqMan®) 
Real-Time RT-PCR reactions were carried out as quadruplicates in a Fast Optical 96-well plate 
(Applied Biosystems, Foster City, CA, USA). A total of 1 µL of the prepared cDNA was mixed with  
1 µL TaqMan® Gene Expression Assay (CK18 (Hs_01920599_gH), Her2 (Hs_00170433_m1) MGL 
(Hs_00419570_m1) and GAPDH (Hs_99999905_m1)), 10 µL TaqMan® Fast Universal PCR Master 
Mix (all Applied Biosystems), and 8 µL PCR-grade water per sample was prepared and pipetted into 
the respective wells on a PCR plate. The same mix was used for the housekeeping/reference gene  
B2M [42,43] together with a FAM-Tamra primer mix (Biomers, Ulm, Germany). For CK8, 19 and 
BCSP the PCR product of the nested PCR were inserted for real-time RT-PCR. Primer sequences are 
presented in Table 5. After its sealing with an adhesive cover (Applied Biosystems), samples were 
analysed on a 7500 Fast Real-Time PCR machine (Applied Biosystems). We used an established 
setting for the PCR runs: One enzyme activation cycle at 95 °C for 20 s, 40 cycles at 95 °C for 3 s and 
60 °C for 30 s. Fluorescence was measured in every step and displayed by the provided SDS 1.3.1 
software (Applied Biosystems, 2001–2005, Foster City, CA, USA). Non-template-, and-RT controls 
were also implemented in the experimental setting. PCR efficiency of TaqMan Primers from Applied 
Biosystems is stated with 100% ± 10% by the provider. PCR efficiency of RealTime RT-PCR Primers 
for CK8, CK19, BCSP and B2M was analyzed by a standard curve assay and is shown in Table 6. 
Table 5. Primer & Probes used for Real-Time RT-PCR. 
Gene  Forward primer Reverse primer Hydrolysis probe 
B2M 5'-ggccgagatggctccg-3' 5'-gatgaaaccccatagc-3' 5'-aggctatccagattca-3' 
CK8 5'-cctacaggaagctgga-3' 5'-gctcagaccaatagcc-3' 5'-ggagagccggggagtc-3' 
CK19 5'-ccgaggttacacctgc-3' 5'-gatcagcgccgatatg-3' 5'-ctgagcatgagctgcc-3' 
BCSP 5'-ggagaacatcgtcacc-3' 5'-ggatgcctcactcctg-3' 5'-tgcgcaaggagaggcc-3' 
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Table 6. PCR efficiency of Real-Time RT-PCR Primers drawn by standard curve assay. 
Gene R2-value PCR efficiency 
B2M 0,9845 98,45% 
CK8 0,9923 99,23% 
CK19 0,9066 90,66% 
BCSP 0,9894 98,94% 
3.7. Evaluation 
Data from SDS software V.1.3.1 were transferred into Microsoft® Excel™, evaluated, and 
clustered column charts generated. Relative expression rates are calculated by 2−ΔΔCT formula [44]. 
Relative expression values >1 were considered upregulated for the respective gene in a certain sample 
in comparison to negative control samples. Negative controls consisted of mean gene expressions of 
blood samples spent by healthy donors. Non-template control and RT control assays did not yield any 
fluorescent signals. 
4. Conclusions  
In the future more marker genes will have to be tested for their benefit in the detection of breast 
cancer cells in the blood stream. A combination of various markers could potentially help detect 
tumor-cell-specific mRNA, as already described by Gervasoni et al. [45] and Bölke et al. [46]. Taking 
these considerations into account, the method presented in this study contributes largely to detection of 
cancer cells in patients’ blood. Ultimately, detailed characterization of CTCs leads to better diagnosis 
as well as prognosis and could help in choosing the adequate therapy. 
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